![]() |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
◆ 会议时间:2025年11月5-9日
◆ 会议简介: 2025年第40届癌症免疫治疗学会(SITC)年会将于2025年11月5-9日在美国国家海港举行。SITC年会是世界上最大的专注于癌症免疫治疗的国际盛会,每年的会议和会前教育计划都会吸引超过3500名来自学术界、监管部门和政府机构宣的国际行业领袖与代表。SITC为与会者提供了一个多学科的教育和互动平台,共同推动科学进步,发现突破性的进展,力求改善所有癌症患者的预后(未经许可,禁止复制摘录转载本站任何内容-领域国际医学会议网)。 癌症免疫治疗学会(SITC)成立于1984年,是世界领先的专业致力于通过推进癌症免疫治疗科学与应用来改善癌症患者预后的非营利组织,SITC为来自世界各地的科学家、学者、研究人员、临床医生、政府代表和行业领导者提供服务。目前,SITC拥有超过1700名成员,代表17种医疗专业,从事至少十几种癌症的研究和治疗。SITC的愿景是通过促进科学交流与合作教育计划,旨在让癌症患者被“治愈”在某一天能够成为现实。 40th Annual Meeting & Pre-Conference Programs of the The Society for Immunotherapy of Cancer (SITC 2025) Date: Venue:
The SITC Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy. As the largest conference solely focused on cancer immunotherapy, the Annual Meeting & Pre-Conference Programs provides international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.
以下为往届会议信息,仅供参考! The Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting & Pre-Conference Programs (SITC 2024)
SITC 2024 摘要征文投稿: Regular, Young Investigator Award (YIA), and Immune Engineering Abstract DatesApril 24, 2024 June 27, 2024 Aug. 2, 2024 Aug. 9, 2024 Oct. 4, 2024 Nov. 5, 2024 Nov. 6–10, 2024 Feb. 2025
Late-Breaking Abstracts – Clinical Only (LBA) DatesJuly 15, 2024 Sept. 12, 2024 Sept. 25, 2024 Sept. 30, 2024 Oct. 30, 2024 Nov. 5, 2024 Nov. 6–10, 2024 Feb. 2025
Abstract TypesNew for SITC 2024 – Call for Immune Engineering AbstractsThis year the Pre-Conference Program, Immune Engineering Workshop, on Thursday, Nov. 7, from 9 a.m.–5 p.m., will offer additional opportunities for poster and oral presentations. Abstracts that focus on immune engineering and related topics will be eligible for this opportunity. Abstract submitters will be able to select if they would like their abstract considered for the Immune Engineering Workshop within the Regular and YIA Submission Portal. Regular AbstractsThe time frame to submit your latest research in the cancer immunotherapy field to the 39th Annual Meeting for consideration as an oral abstract presentation and/or poster abstract presentation is April 24, 2024 until 5 p.m. PDT on June 27, 2024. Young Investigator Award (YIA) AbstractsRegular Abstracts with primary and presenting authors that are students, postdoctoral research fellows, clinical fellows, or junior faculty with three or fewer years on staff and are current SITC members, may be eligible to receive a Young Investigator Award (YIA). Five YIAs will be reserved for those who self-identify as individuals from underrepresented racial and ethnic groups in the Biomedical Sciences according to the NIH definition. YIA Abstracts require a letter of recommendation as well as additional information regarding the percentage of contribution by the primary and presenting author. The time frame to submit a YIA Abstract to the 39th Annual Meeting is April 24, 2024 until 5 p.m. PDT on June 27, 2024. Those selected for the Presidential Travel Award will be invited to give an oral abstract presentation during the Presidential Session from 1:30–2:55 p.m. on Saturday, Nov. 9, 2024 (session time subject to change). An abstract submitted for a YIA that does not receive an award may still be accepted as an abstract for SITC 2024 and will be considered a Regular Abstract. For more information about the YIAs as well as the criteria and eligibility, please click here. Late-Breaking Abstracts – Clinical Only (LBA)Late-breaking Abstract – Clinical Only (LBA) submission is solely for abstracts with late-breaking data from interventional clinical trials in humans and not for abstracts submitted “late”. The LBA deadline is not intended to be an extension of the general submission deadline. LBAs highlight novel and practice-changing in-human clinical studies and only apply to data that would have not otherwise have been presented as an abstract at the 39th Annual Meeting. Authors of LBAs do not need to submit an application or a place-holder abstract. LBAs should be submitted during the LBA submission period, from July 15–Sept. 12 at 5 p.m. PDT. If a LBA is not accepted, it will not be published or presented at the meeting. There is no longer an option for it to be considered as a Regular/YIA Abstract. LBAs are considered for a limited allocation of oral and poster presentation slots on either Friday, Nov. 8 or Saturday, Nov. 9.
注册费: Annual Meeting (Fri., Sat., Sun.)ROOM: Various
PRE-CONFERENCE PROGRAMS Rates for each of the following Pre-Conference Programs:
Grant Writing WorkshopROOM: Level 2 – Houston Ballroom, Salon 2 – Marriott Marquis
|
© 版权声明
本文由分享者转载或发布,内容仅供学习和交流,版权归原文作者所有。如有侵权,请留言联系更正或删除。